Claims for Patent: 8,580,293

Summary for Patent: 8,580,293

Title:	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
Abstract:	The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
Inventor(s):	Ahmed; Salah U. (New City, NY), Tsao; Jiaxiang (Nanuet, NY), Mahashabde; Anu (Kendall Park, NY), Harrison; Diane D. (Villanova, PA)
Assignee:	Teva Women's Health, Inc. (Woodcliff Lake, NJ)
Application Number:	12/364,990
Patent Claims:	1. A method for treating a luteal phase defect in a patient in need thereof, the method comprising administering to the patient a monolithic intravaginal ring comprising: (a) a therapeutically effective amount of progesterone; (b) a polysiloxane elastomer; and (c) a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid, wherein the polysiloxane elastomer is present in a concentration of about 55% to about 90% by total weight of the ring, and wherein the pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid is present in a concentration of about 5% to about 10% by total weight of the ring. 2. The method of claim 1, wherein the polysiloxane elastomer is a diorganopolysiloxane elastomer. 3. The method of claim 2, wherein the diorganopolysiloxane elastomer is dimethylpolysiloxane elastomer. 4. The method of claim 3, wherein the dimethylpolysiloxane elastomer further comprises a dimethylmethylhydrogen polysiloxane crosslink. 5. The method of claim 1, wherein the progesterone is present in a concentration of about 15% to about 30% by total weight of the ring. 6. The method of claim 1, wherein the polysiloxane elastomer is a dimethylpolysiloxane elastomer, and wherein the ratio of progesterone to elastomer is about 1:1 to about 1:10, the progesterone is homogeneously dispersed in the elastomer, the ratio of progesterone to hydrocarbon or glycerol esters of a fatty acid is about 1:0.1 to about 1:100, and wherein the progesterone is released from the monolithic intravaginal ring for up to about 18 days after administration to the patient. 7. The method of claim 1, wherein the intravaginal ring comprises: (a) about 15% to about 25% by weight of the progesterone; (b) about 70% to about 80% by weight of a dimethylpolysiloxane elastomer; and (c) about 5% to about 10% by weight of the pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid, wherein the progesterone is homogeneously dispersed in the elastomer, and wherein the progesterone is released from the monolithic intravaginal ring for up to about 18 days after administration to the patient. 8. A method for treating a luteal phase defect in a patient in need thereof, the method comprising administering to the patient a monolithic intravaginal ring comprising: (a) a therapeutically effective amount of progesterone; (b) a polysiloxane elastomer; and (c) a pharmaceutically acceptable oil, wherein the polysiloxane elastomer is present in a concentration of about 55% to about 90% by total weight of the ring, wherein the pharmaceutically acceptable oil is present in a concentration of about 5% to about 10% by total weight of the ring. 9. The method of claim 8, wherein the polysiloxane elastomer is a diorganopolysiloxane elastomer. 10. The method of claim 9, wherein the diorganopolysiloxane elastomer is dimethylpolysiloxane elastomer. 11. The method of claim 10, wherein the dimethylpolysiloxane elastomer further comprises a dimethylmethylhydrogen polysiloxane crosslink. 12. The method of claim 8, wherein the pharmaceutically acceptable oil is selected from mineral oil, silicone oil and combinations thereof. 13. The method of claim 8, wherein the pharmaceutically acceptable oil is mineral oil. 14. The method of claim 8, wherein the progesterone is present in a concentration of about 15% to about 30% by total weight of the ring. 15. The method of claim 8, wherein the intravaginal ring comprises: the progesterone, a dimethylpolysiloxane elastomer, and a pharmaceutically acceptable oil, in a ratio of about 4:15:1, respectively, wherein the progesterone is homogeneously dispersed in the elastomer, and wherein the progesterone is released from the monolithic intravaginal ring for up to about 18 days after administration to the patient. 16. The method of claim 8, wherein the intravaginal ring comprises: (a) about 15% to about 25% by weight of the progesterone; (b) about 70% to about 80% by weight of a dimethylpolysiloxane elastomer; and (c) about 5% to about 10% by weight of a pharmaceutically acceptable oil, wherein the progesterone is homogeneously dispersed in the elastomer, and wherein the progesterone is released from the monolithic intravaginal ring for up to about 18 days after administration to the patient. 17. A method of supporting embryo implantation and early pregnancy in a patient in need thereof, the method comprising administering to the patient a monolithic intravaginal ring comprising: i. a therapeutically effective amount of progesterone; ii. a polysiloxane elastomer; and iii. a pharmaceutically acceptable hydrocarbon or glycerol ester of a fatty acid, where the polysiloxane elastomer is present in a concentration of about 55% to about 90% by total weight of the ring, wherein the pharmaceutically acceptable hydrocarbon or glycerol ester of a fatty acid is about 5% to about 10% by total weight of the ring. 18. The method of claim 17, wherein the patient in need thereof is undergoing an assisted reproductive treatment program. 19. The method of claim 17, wherein the patient in need thereof is otherwise infertile. 20. The method of claim 17, wherein the administering is for about 7 days. 21. The method of claim 17, wherein the intravaginal ring is replaced about every 7 days for about 10 weeks with a new intravaginal ring as described in (i)-(iii).